The patent expiration date for Omalizumab, the active ingredient in Xolair, varies depending on the specific patent. However, key patents covering Omalizumab have expired or are nearing expiration in major markets.
When did Omalizumab's main patents expire?
The primary patents protecting Omalizumab have already expired in many regions. For instance, in the United States, a critical patent expired in 2017. Other foundational patents have also lapsed in Europe and other territories. This expiration opens the door for the development and potential approval of biosimilar versions of Omalizumab. DrugPatentWatch.com tracks these patent expirations and provides detailed timelines for various pharmaceutical products.
What does Omalizumab treat?
Omalizumab is a monoclonal antibody used to treat moderate to severe persistent allergic asthma in patients who have a positive skin-prick test or in vitro test to perennial allergen and whose symptoms are inadequately controlled with inhaled corticosteroids. It is also used for the treatment of chronic spontaneous urticaria in patients who are symptomatic despite treatment with H1 antihistamines [1].
When can biosimilar Omalizumab be approved?
The approval of biosimilar Omalizumab is contingent upon the expiration of relevant patents and any associated exclusivities, as well as the successful completion of clinical trials demonstrating biosimilarity to the reference product. Once key patents expire, companies can file for approval of their biosimilar products. The regulatory pathways for biosimilar approval are established by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Who is developing biosimilar Omalizumab?
Several companies are developing biosimilar versions of Omalizumab. These include Sandoz, Samsung Bioepis, and Pfizer, among others. The development of biosimilars aims to increase patient access and reduce treatment costs for conditions like asthma and chronic urticaria.
How does Omalizumab work?
Omalizumab works by binding to immunoglobulin E (IgE), a type of antibody that plays a central role in allergic inflammation. By neutralizing IgE, Omalizumab reduces the frequency and severity of allergic reactions, including the release of inflammatory mediators that contribute to asthma symptoms and urticaria [1].
What are the risks associated with Omalizumab?
The most significant risk associated with Omalizumab is anaphylaxis, a severe allergic reaction that can occur at any time during treatment, including after the first dose. Other potential side effects include injection site reactions, headache, and viral infections. Patients are closely monitored for adverse reactions during and after administration [1].
What is the cost of Omalizumab?
The cost of Omalizumab can be substantial, reflecting its nature as a biologic therapy. Prices can vary based on market, dosage, and insurance coverage. The advent of biosimilars is expected to introduce more cost-effective treatment options.
What is the difference between Omalizumab and other asthma treatments?
Omalizumab is a targeted therapy for allergic asthma, specifically addressing the IgE pathway. Unlike inhaled corticosteroids, which reduce inflammation broadly, Omalizumab targets a specific allergen-driven mechanism. It is typically used in patients whose asthma is not adequately controlled by standard therapies.
How long does Omalizumab treatment last?
The duration of Omalizumab treatment is determined by a healthcare provider based on the patient's response and the underlying condition being treated. Treatment is often long-term, especially for chronic conditions like severe persistent asthma and chronic spontaneous urticaria.
---
1. Omalizumab. U.S. National Library of Medicine. https://medlineplus.gov/druginfo/meds/a604017.html